Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment

Daichi Tsukada; Katsumi Iizuka; Ken Takao; Yanyan Liu; Sodai Kubota; Saki Okamoto-Kubota; Teruaki Sakurai; Toshinori Imaizumi; Mayu Sakai; Takehiro Kato; Masami Mizuno; Takuo Hirota; Tetsuya Suwa; Yukio Horikawa; Mayumi Yamamoto; Sumihisa Kubota; Daisuke Yabe

doi:10.2169/internalmedicine.8710-21

Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment

Daichi Tsukada, Katsumi Iizuka, Ken Takao, Yanyan Liu, Sodai Kubota, Saki Okamoto-Kubota, Teruaki Sakurai, Toshinori Imaizumi, Mayu Sakai, Takehiro Kato, Masami Mizuno, Takuo Hirota, Tetsuya Suwa, Yukio Horikawa, Mayumi Yamamoto, Sumihisa Kubota, Daisuke Yabe

臨床栄養学

研究成果: Article › 査読

抄録

We treated a 22-year-old woman suffering from Graves' disease and thymic hyperplasia. She was referred to our institution for a close investigation of thyrotoxicosis and thymic mass. Thyroid tests and magnetic resonance imaging resulted in a diagnosis of Graves' disease and thymic hyperplasia. The thyroid function and thyroid-stimulating hormone receptor antibody (TRAb) were normalized one and five months after thiamazole initiation, respectively. The thymic size began to decrease after 1 month and was further decreased after 5 months; it was normalized after 12 months. The correlation between TRAb titers and the thymic size (R2=0.99) suggested that the patient's autoimmunity might have contributed to the thymic hyperplasia.

本文言語	English
ページ（範囲）	2753-2757
ページ数	5
ジャーナル	Internal Medicine
巻	61
号	18
DOI	https://doi.org/10.2169/internalmedicine.8710-21
出版ステータス	Published - 2022

All Science Journal Classification (ASJC) codes

内科学

文献へのアクセス

10.2169/internalmedicine.8710-21

他のファイルとリンク

フィンガープリント

「Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Tsukada, D., Iizuka, K., Takao, K., Liu, Y., Kubota, S., Okamoto-Kubota, S., Sakurai, T., Imaizumi, T., Sakai, M., Kato, T., Mizuno, M., Hirota, T., Suwa, T., Horikawa, Y., Yamamoto, M., Kubota, S., & Yabe, D. (2022). Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment. Internal Medicine, 61(18), 2753-2757. https://doi.org/10.2169/internalmedicine.8710-21

@article{77623bd0b8694ea38b5a98992fa99d40,

title = "Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment",

abstract = "We treated a 22-year-old woman suffering from Graves' disease and thymic hyperplasia. She was referred to our institution for a close investigation of thyrotoxicosis and thymic mass. Thyroid tests and magnetic resonance imaging resulted in a diagnosis of Graves' disease and thymic hyperplasia. The thyroid function and thyroid-stimulating hormone receptor antibody (TRAb) were normalized one and five months after thiamazole initiation, respectively. The thymic size began to decrease after 1 month and was further decreased after 5 months; it was normalized after 12 months. The correlation between TRAb titers and the thymic size (R2=0.99) suggested that the patient's autoimmunity might have contributed to the thymic hyperplasia.",

author = "Daichi Tsukada and Katsumi Iizuka and Ken Takao and Yanyan Liu and Sodai Kubota and Saki Okamoto-Kubota and Teruaki Sakurai and Toshinori Imaizumi and Mayu Sakai and Takehiro Kato and Masami Mizuno and Takuo Hirota and Tetsuya Suwa and Yukio Horikawa and Mayumi Yamamoto and Sumihisa Kubota and Daisuke Yabe",

year = "2022",

doi = "10.2169/internalmedicine.8710-21",

language = "English",

volume = "61",

pages = "2753--2757",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "18",

}

Tsukada, D, Iizuka, K, Takao, K, Liu, Y, Kubota, S, Okamoto-Kubota, S, Sakurai, T, Imaizumi, T, Sakai, M, Kato, T, Mizuno, M, Hirota, T, Suwa, T, Horikawa, Y, Yamamoto, M, Kubota, S & Yabe, D 2022, 'Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment', Internal Medicine, vol. 61, no. 18, pp. 2753-2757. https://doi.org/10.2169/internalmedicine.8710-21

TY - JOUR

T1 - Graves' Disease with Thymic Hyperplasia

T2 - The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment

AU - Tsukada, Daichi

AU - Iizuka, Katsumi

AU - Takao, Ken

AU - Liu, Yanyan

AU - Kubota, Sodai

AU - Okamoto-Kubota, Saki

AU - Sakurai, Teruaki

AU - Imaizumi, Toshinori

AU - Sakai, Mayu

AU - Kato, Takehiro

AU - Mizuno, Masami

AU - Hirota, Takuo

AU - Suwa, Tetsuya

AU - Horikawa, Yukio

AU - Yamamoto, Mayumi

AU - Kubota, Sumihisa

AU - Yabe, Daisuke

PY - 2022

Y1 - 2022

N2 - We treated a 22-year-old woman suffering from Graves' disease and thymic hyperplasia. She was referred to our institution for a close investigation of thyrotoxicosis and thymic mass. Thyroid tests and magnetic resonance imaging resulted in a diagnosis of Graves' disease and thymic hyperplasia. The thyroid function and thyroid-stimulating hormone receptor antibody (TRAb) were normalized one and five months after thiamazole initiation, respectively. The thymic size began to decrease after 1 month and was further decreased after 5 months; it was normalized after 12 months. The correlation between TRAb titers and the thymic size (R2=0.99) suggested that the patient's autoimmunity might have contributed to the thymic hyperplasia.

AB - We treated a 22-year-old woman suffering from Graves' disease and thymic hyperplasia. She was referred to our institution for a close investigation of thyrotoxicosis and thymic mass. Thyroid tests and magnetic resonance imaging resulted in a diagnosis of Graves' disease and thymic hyperplasia. The thyroid function and thyroid-stimulating hormone receptor antibody (TRAb) were normalized one and five months after thiamazole initiation, respectively. The thymic size began to decrease after 1 month and was further decreased after 5 months; it was normalized after 12 months. The correlation between TRAb titers and the thymic size (R2=0.99) suggested that the patient's autoimmunity might have contributed to the thymic hyperplasia.

UR - http://www.scopus.com/inward/record.url?scp=85138447712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138447712&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.8710-21

DO - 10.2169/internalmedicine.8710-21

M3 - Article

C2 - 35228417

AN - SCOPUS:85138447712

VL - 61

SP - 2753

EP - 2757

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 18

ER -